Title of article
Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death
Author/Authors
Ricci، نويسنده , , M. Stacey and Kim، نويسنده , , Seok-Hyun and Ogi، نويسنده , , Kazuhiro and Plastaras، نويسنده , , John P. and Ling، نويسنده , , Jianhua and Wang، نويسنده , , Wenge and Jin، نويسنده , , Zhaoyu and Liu، نويسنده , , Yingqiu Y. and Dicker، نويسنده , , David T. and Chiao، نويسنده , , Paul J. and Flaherty، نويسنده , , Keith T. and Smith، نويسنده , , Charles D. and El-Deiry، نويسنده , , Wafik S. El-Deiry and Yigong Shi، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2007
Pages
15
From page
66
To page
80
Abstract
Summary
expressing oncogenic c-Myc are sensitized to TNF superfamily proteins. c-Myc also is an important factor in determining whether a cell is sensitive to TRAIL-induced apoptosis, and it is well established that the mitochondrial pathway is essential for apoptosis induced by c-Myc. We investigated whether c-Myc action on the mitochondria is required for TRAIL sensitivity and found that Myc sensitized cells with defective intrinsic signaling to TRAIL. TRAIL induced expression of antiapoptotic Mcl-1 and cIAP2 through activation of NF-κB. Both Myc and the multikinase inhibitor sorafenib block NF-κB. Combining sorafenib with TRAIL in vivo showed dramatic efficacy in TRAIL-resistant tumor xenografts. We propose the combination of TRAIL with sorafenib holds promise for further development.
Keywords
CELLCYCLE
Journal title
Cancer Cell
Serial Year
2007
Journal title
Cancer Cell
Record number
1336467
Link To Document